In patients with ATD, there is wide agreement among the guidelines to suggest anti-transglutaminase antibodies (tTG) immunoglobulin A (IgA) as the initial serological screening test for CD, complemented by a determination of total IgA levels to exclude IgA deficiency as shown in Figure 2. This evidence concerns the gene TGM2 and selective IgA deficiency disease.